Clik here to view.
Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its...
View ArticleClik here to view.
Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain
Denali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases. The...
View ArticleClik here to view.
Kala Pharma reveals mixed Ph3 data for dry eye disease drug
Kala Pharmaceuticals (NSDQ:KALA) shares dropped -28% today after the company revealed mixed results from two Phase III trials of its dry eye disease drug, KPI-121. In its Stride 1 trial, the company’s...
View ArticleClik here to view.
Facing competition for Restasis, Allergan moves to cut costs by slashing...
Allergan (NYSE:AGN) said this week that it plans to cut more than 5% of its workforce in an attempt to cut costs. The drug-maker is facing competition from up-coming generics to its dry-eye drug,...
View ArticleClik here to view.
Insulet lands Medicare Part D coverage for Omnipod insulin delivery system
The Centers for Medicare and Medicaid Services issued guidance today noting that Insulet‘s (NSDQ:PODD) Omnipod tubeless insulin delivery device can be covered by the Medicare Part D prescription drug...
View ArticleClik here to view.
pSivida seeks FDA nod for 3-year treatment of posterior segment uveitis
pSivida (NSDQ:PSDV) has submitted a new drug application to the FDA for its Durasert implant that provides three years of treatment for people with posterior segment uveitis. The drug-delivery...
View ArticleClik here to view.
Intersect ENT reports Q4, full-year revenue prelims
Shares in Intersect ENT (NSDQ:XENT) held steady today after the company reported preliminary data for its fourth quarter and full-year revenues. The Menlo Park, Calif.-based company said it expects to...
View ArticleClik here to view.
Attune Medical wins 510(k) clearance for drug-delivery model of EnsoETM...
Attune Medical said today that it won 510(k) clearance from the FDA for a new model of its EnsoETM device capable of administering tube feeds or medication while regulating a patient’s temperature...
View ArticleClik here to view.
Novocure revenues climb in Q4, FY17 prelims
Novocure (NSDQ:NVCR) shares rose slightly this morning after the cancer-treatment developer reported its preliminary fourth quarter and full-year revenues. The St. Helier, N.J.-based company said it...
View ArticleClik here to view.
Allergan talks taxes and competition in 2018 outlook
Allergan (NYSE:AGN) had a busy, and occasionally fraught, 2017. After the company inked a controversial deal with a Native American tribe to shield its Restasis patents from review, a federal judge in...
View ArticleClik here to view.
Ascensia inks global distro sale with Insulet for blood glucose monitor
Ascensia Diabetes Care has expanded its partnership with Insulet (NSDQ:PODD) to include a global commercial deal. The two companies inked a world-wide development agreement in June last year to connect...
View ArticleClik here to view.
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Health Canada has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection as an adjunct to diet and exercise that can help adults with Type II diabetes control their blood sugar levels....
View ArticleClik here to view.
FDA approves clinician app for Medtronic’s SynchroMed II drug pump
The FDA has approved a new clinician application for Medtronic‘s (NYSE:MDT) SynchroMed II intrathecal drug pump. The newly-approved programmer was designed to give doctors visual tools and improved...
View ArticleClik here to view.
At confirmation hearing for Trump’s HHS nominee, drug pricing takes center-stage
Alex Azar, the president’s nominee to head the Dept. of Health & Human Services, has nearly a decade of experience in the pharmaceutical industry – and that experience is either predictive of his...
View ArticleClik here to view.
Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive...
View ArticleClik here to view.
GenSight to launch trial of gene therapy, visual stimulation device combo in UK
The UK’s Medicines and Healthcare Regulatory Agency has approved GenSight Biologics‘ (EPA:SIGHT) application to combine gene therapy and a wearable optronic visual stimulation device in patients with...
View ArticleClik here to view.
Eyenovia sets range for IPO
N.Y.-based startup Eyenovia updated its regulatory filings to reveal that it plans to offer 2.73 million shares priced between $10 – $12 apiece in its initial public offering. The 7-person company,...
View ArticleClik here to view.
Svelte Medical launches pivotal trial for drug-eluting stent-on-a-wire
The first patient has been enrolled in Svelte Medical System‘s Optimize pivotal trial, which is designed to evaluate the safety and efficacy of Svelte’s drug-eluting stent integrated delivery system...
View ArticleClik here to view.
Braeburn raises $110m for opioid use disorder depot injection
Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield...
View ArticleClik here to view.
Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent...
Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and...
View Article